REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also ...
The Drill Program is designed to test extensions of known copper-molybdenum mineralization and evaluate new target areas ...
This is Part 2 of our two-part technical analysis on the Gopher Strike and Sheet Attack campaigns. For details on the Gopher Strike campaign, go to Part 1.IntroductionIn September 2025, Zscaler ...
Google Workspace provides a strong baseline, yet default settings expose gaps in email security, access control, and data ...
Data Privacy Day offers a natural checkpoint to take stock of a fast‑moving legal landscape. As of January 1, 2026, several ...
Businesses with a Mac-first strategy have long enjoyed the perception of inherent security from the Unix-based operating ...
DOVER, DE, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- EasyDMARC, a vendor of the cloud-native email security ...
MarketBeat on MSN
Steel Dynamics Reinforces Outlook: Higher Highs Coming
Steel Dynamics (NASDAQ: STLD) is well-positioned as a domestic producer of low-carbon, high-recycled-content steel and steel ...
Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially ...
Huntsman Corporation executes a specialty chemicals pivot while navigating MDI market cycles and cost restructuring. Explore ...
Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) (‘Fathom”, or the “Company”) is pleased to announce, based on very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results